Skip to main content
Midas Edge

AEON Biopharma, Inc.

For the period ended Sep 30, 2025. Filed Nov 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 14, 2025

AEON$0.18-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Deficit

(in thousands, except share data) (Unaudited)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-in · ​ · Subscription · ​ · Accumulated · ​ · Stockholders'
​ · ​ · Shares · ​ · Amount · ​ · Capital · ​ · Receivables · ​ · Deficit · ​ · Deficit
Balance as of January 1, 2025555,511​$4​$403,024​$—​$(431,597)​$(28,569)
Net loss—​—​—​—​(2,085)​(2,085)
Issuance of shares and reclassification of liability related to cashless warrant exercises10,869,856​5​6,884​—​—​6,889
Issuance of shares related to at-the-market offering, net218,419​—​168​—​—​168
Stock-based compensation expense​—​—​3,725​—​—​3,725
Balance as of September 30, 202511,643,786​$9​$413,801​$—​$(433,682)​$(19,872)
​​​​​​​​​​​​​​​​​​
Balance as of January 1, 2024516,404​$4​$381,264​$(60,710)​$(473,602)​$(153,044)
Net income​—​—​—​—​39,923​​39,923
Termination of Forward Purchase Agreements​—​—​—​60,710​—​​60,710
Issuance of shares and reclassification of liability related to cashless warrant exercises​27,310​—​14,979​—​—​​14,979
Issuance of shares related to at-the-market offering, net​916​​—​​50​​—​​—​​50
Issuance of common stock​5,556​​—​​384​​—​​—​​384
Stock-based compensation expense​—​—​4,908​—​—​​4,908
Balance as of September 30, 2024550,186​$4​$401,585​$—​$(433,679)​$(32,090)
​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-in · ​ · Subscription · ​ · ​ · Accumulated · ​ · Stockholders'
​ · ​ · Shares · ​ · Amount · ​ · Capital · ​ · Receivables · ​ · Deficit · ​ · Deficit
Balance as of July 1, 202511,537,870​$9​$413,283​$—​$(429,144)​$(15,852)
Net loss—​$—​$—​$—​$(4,538)​(4,538)
Issuance of shares and reclassification of liability related to cashless warrant exercises​—​$—​$20​$—​$—​​20
Issuance of shares related to at-the-market offering, net​105,916​$—​$84​$—​$—​​84
Stock-based compensation expense​—​$—​$414​$—​$—​​414
Balance as of September 30, 202511,643,786​$9​$413,801​$—​$(433,682)​$(19,872)
​​​​​​​​​​​​​​​​​​
Balance as of July 1, 2024543,714​$4​$399,557​$—​$(427,508)​$(27,947)
Net loss—​—​—​—​(6,171)​(6,171)
Issuance of shares related to cashless warrant exercises​—​​—​​—​​—​​—​​—
Issuance of shares related to at-the-market offering, net​916​​—​​50​​—​​—​​50
Issuance of common stock​5,556​​—​​384​​—​​—​​384
Stock-based compensation expense​—​​—​​1,594​​—​​—​​1,594
Balance as of September 30, 2024550,186​$4​$401,585​$—​$(433,679)​$(32,090)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.